ZIMMER BIOMET HOLDINGS, INC. reported revenue of $2.18B for the period ended 2026-06-30, +4.8% year on year. Net income was $0.20B, a 9.1% net margin on a 70.8% gross margin. The largest revenue line is Knees at 38% of the total. Free cash flow for the period was $0.33B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $2.18B | +4.8% |
| Gross profit | $1.54B | — |
| Operating income | $0.33B | — |
| Net income | $0.20B | +29.8% |
| Gross margin | 70.8% | Net margin 9.1% |
| Revenue Q/Q | +4.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| Knees | $0.83B | 38.1% |
| SET | $0.59B | 26.9% |
| Hips | $0.56B | 25.8% |
| Technology And Data Bone Cement And Surgical | $0.20B | 9.2% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $0.64B | 29.2% |
| SG&A | $0.90B | 41.3% |
| Tax & other | $0.13B | 5.9% |
| Item | Amount |
|---|---|
| Total assets | $22.80B |
| Total liabilities | $10.17B |
| Shareholders' equity | $12.63B |
| Equity / assets | 55.4% |
| Operating cash flow | $0.45B |
| Capital expenditure | $0.12B |
| Free cash flow | $0.33B |
| Cash conversion (OCF / net income) | 226% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
ZTS ・ WST ・ WDC ・ WY ・ WSM ・ WMB ・ WTW ・ WDAY ・ WYNN ・ XEL ・ XYL ・ YUM
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies